FATE
Fate Therapeutics, Inc. (FATE) 10Y Growth Potential Analysis (2026)
Overall Score
Growth Runway
Revenue base remains very small at a revenuePerShareTTM of 0.0539, limiting near-term scale.
No evidence of durable top-line expansion in the fresh TTM metrics, and profitability remains deeply negative.
Profitability
TTM margins remain sharply negative, including grossProfitMarginTTM of -3.43, operatingProfitMarginTTM of -20.58, and netProfitMarginTTM of -19.41.
Returns on capital are still deeply negative, with returnOnEquityTTM of -0.65 and returnOnInvestedCapitalTTM of -0.57.
Financial Strength
Liquidity is strong with currentRatioTTM of 4.85 and cashRatioTTM near 1.0.
Balance sheet leverage is manageable, with debtToEquityRatioTTM of 0.49 and netDebtToEBITDATTM of -0.37.
Cash Generation
Cash flow remains negative, with operatingCashFlowTTM of -3.20 and freeCashFlowTTM of -3.09 on an EV basis.
Free cash flow yieldTTM is negative at -0.37, indicating the business is still consuming cash.
Valuation
Valuation remains demanding on sales, with evToSalesTTM of 50.30 and priceToSalesRatioTTM of 43.64.
Traditional earnings-based multiples are not meaningful given persistent losses, so the stock still depends on future execution.
Execution Risk
Operating efficiency remains weak, with assetTurnoverRatioTTM of 0.025 and operatingCashFlowSalesRatioTTM of -15.71.
High R&D intensity at 15.01% of revenue supports pipeline investment but also underscores ongoing burn and execution risk.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Fate Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

